We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Biomarkers In Seizure To Predict Recurrence and Severe Outcomes (BISTRO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01774500
Recruitment Status : Completed
First Posted : January 24, 2013
Last Update Posted : March 27, 2014
Sponsor:
Collaborators:
Groupe Hospitalier Pitie-Salpetriere
Barts & The London NHS Trust
Information provided by (Responsible Party):
Yonathan Freund, Bistro Study Group

Brief Summary:
We study the hypothesis that combination of Proteine S100 beta and Copeptin within normal ranges can rule out seizure recurrences and severe outcome, and allow early discharge from the emergency department

Condition or disease
Seizures S-100b Protein Copeptin

Detailed Description:

Prospective study for a 12 month period in Paris (France) and London (UK).

Inclusion criteria :

  • seizure within 24h of attendance to an Emergency department (ED)
  • or seizure in the ED

Exclusion Criterie :

  • pregnancy
  • prisoneer

Primary endpoint :

- recurrence of seizure, hospitalisation more than 24 hours or death within seven days

Secondary endpoint :

  • Hospital free days at day 7 and day 28
  • Death, ICU admission, or neurosurgical intervention at day 7 and day 28
  • Return visit to the ED or re admission at day 7 and day 28

data collection:

  • demographics
  • past medical history, medication
  • vital signs (Heart rate, temperature, Pulse oxymetry, blood pressure, GCS) on arrival
  • Pathology (White cell count, Sodium, Calcium, Glucose, lactate)
  • Protein S100B and Copeptin
  • Seizure characteristics (Witnessed, simple, partial, complex, provoked, acute symptomatic, idiopathic)
  • Discharge plan, outcomes

Follow up at day 7 and day 28, hospital visit or phone call


Study Type : Observational [Patient Registry]
Estimated Enrollment : 300 participants
Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration: 1 Month
Official Title: Study of Prognosis Value of Protein S100Beta and Copeptine in Seizure in the Emergency Department
Study Start Date : January 2013
Primary Completion Date : January 2014
Study Completion Date : March 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Seizures
U.S. FDA Resources




Primary Outcome Measures :
  1. Combined hospital admission, seizure recurrence, or death at day 7 [ Time Frame: 7 days ]

Secondary Outcome Measures :
  1. Hospital free days [ Time Frame: 7 days ]
    number of days out of hospital, death corresponding to 0

  2. Hospital free days [ Time Frame: day 28 ]
  3. death or ICU admission [ Time Frame: day 7 ]
  4. Death or ICU admission [ Time Frame: 28 days ]
  5. Recurrence of seizure [ Time Frame: 7 days ]

Biospecimen Retention:   Samples Without DNA
2 5ml serum sample for proteine S100Beta and copeptine analysis


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Emergency department patients
Criteria

Inclusion Criteria:

  • Seizure within 24 hours of ED attendance
  • Or Seizure in the ED

Exclusion Criteria:

  • Pregnancy
  • Prisoner
  • age < 18 years old

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01774500


Locations
France
Hopital Lariboisiere
Paris, France, 75010
Groupe Hospitalier pitie-salpetriere
Paris, France, 75013
Hopital Tenon
Paris, France, 75020
United Kingdom
Royal London Hospital, Barts Health NHS Trust
London, United Kingdom, E1 1BB
Sponsors and Collaborators
Bistro Study Group
Groupe Hospitalier Pitie-Salpetriere
Barts & The London NHS Trust

Responsible Party: Yonathan Freund, Chef de Clinique - Research fellow. MD, Bistro Study Group
ClinicalTrials.gov Identifier: NCT01774500     History of Changes
Other Study ID Numbers: BISTRO
First Posted: January 24, 2013    Key Record Dates
Last Update Posted: March 27, 2014
Last Verified: March 2014

Keywords provided by Yonathan Freund, Bistro Study Group:
biomarkers
Emergency Department
Seizures
epilepsy
S100b
copeptin

Additional relevant MeSH terms:
Seizures
Diabetes Insipidus
Epilepsy
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurologic Manifestations
Signs and Symptoms
Kidney Diseases
Urologic Diseases
Pituitary Diseases
Endocrine System Diseases